Embedded Files
IMARC Group’s report titled “Antisense & RNAi Therapeutics Market Report by Technology (RNA Interference, Antisense RNA), Route of Administration (Intravenous Route, Subcutaneous Route, Intrathecal Route, Pulmonary Delivery, Intraperitoneal Injection, and Others), Application (Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Renal Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases, and Others), and Region 2024-2032”. The global antisense & RNAi therapeutics market size reached US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.25% during 2024-2032.
Grab a sample PDF of this report: https://www.imarcgroup.com/antisense-rnai-therapeutics-market/requestsample
Factors Affecting the Growth of the Antisense and RNAi Therapeutics Industry:
Technological Advancements:
Innovations in molecular biology and drug delivery systems benefit in enhancing the potential of antisense and RNA interference (RNAi) therapeutics. In line with this, the development of new techniques in RNAi and antisense technology allows for more precise targeting of specific genes, leading to therapies that are more effective and have fewer side effects. Furthermore, advancements in lipid nanoparticle carriers and conjugate technologies improve the delivery of RNAi therapeutics and overcome previous challenges of stability and off-target effects, which is bolstering the market growth. These technological advancements benefit in increasing the efficiency and safety of treatments.
Rising Prevalence of Chronic Diseases:
The increasing prevalence of various chronic diseases, such as cancer, cardiovascular diseases, and genetic disorders, among the masses across the globe is supporting the growth of the market. In addition, the growing demand for advanced and effective treatment options is offering a positive market outlook. Besides this, antisense and RNAi therapies offer a promising solution due to their ability to specifically target and silence disease-causing genes. These therapies can directly intervene at the molecular level, providing a more precise and potentially more effective approach to managing chronic diseases, unlike traditional treatments.
Favorable Regulatory Framework:
The rising adoption of antisense and RNAi therapeutics due to favorable regulatory approvals is contributing to the growth of the market. Apart from this, regulatory approvals are a testament to the safety and efficacy of therapy and are crucial for introducing a new drug to market. In addition, regulatory authorities provide guidance and frameworks for clinical trials and drug development, ensuring that these processes are conducted safely and effectively. Furthermore, these favorable frameworks encourage pharmaceutical and biotech companies to invest in and develop new antisense and RNAi therapies, which is propelling the market growth.
Leading Companies Operating in the Global Antisense and RNAi Therapeutics Industry:
Alnylam Pharmaceuticals Inc.
Arbutus Biopharma Corporation
Arrowhead Pharmaceuticals Inc.
Benitec Biopharma Ltd.
Bio-Path Holdings Inc.
Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
Ionis Pharmaceuticals Inc.
OliX Pharmaceuticals Inc.
Phio Pharmaceuticals Corp.
Sarepta Therapeutics Inc.
Silence Therapeutics
Sirnaomics Inc
Antisense and RNAi Therapeutics Market Report Segmentation:
By Technology:
RNA Interference
siRNA
miRNA
Antisense RNA
Antisense RNA represents the largest segment as it is effective in targeting genetic disorders, cancers, and viral infections.
By Route of Administration:
Intravenous Route
Subcutaneous Route
Intrathecal Route
Pulmonary Delivery
Intraperitoneal Injection
Others
Pulmonary delivery holds the biggest market share due to the rising cases of respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), and pulmonary infections.
By Application:
Oncology
Cardiovascular Diseases (CVDs)
Respiratory Disorders
Renal Diseases
Neurodegenerative Disorders
Genetic Disorders
Infectious Diseases
Others
On the basis of the application, the market has been divided into oncology, cardiovascular diseases (CVDs), respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and others.
Regional Insights:
North America (United States, Canada)
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa
North America enjoys the leading position in the antisense and RNAi therapeutics market on account of the highly developed biomedical research infrastructure.
Global Antisense and RNAi Therapeutics Market Trends:
The increasing awareness among healthcare professionals and patients about the benefits of targeted therapies, including antisense and RNAi, is contributing to the growth of the market. In line with this, the rising acceptance of these novel treatments among individuals is supporting the market growth.
Apart from this, strategic alliances between biotech and pharmaceutical companies are bolstering the market growth. In addition, these collaborations focus on developing and commercializing new therapies, combining expertise and resources, which is impelling the market growth.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
Page updated
Google Sites
Report abuse